1. Efficacité du bévacizumab dans le traitement de l’œdème maculaire secondaire à une occlusion veineuse rétinienne : à propos de 30 cas.
- Author
-
El Mhadi, Mohcine, Hajjaji, Adel, and El ouaf, Aziz
- Subjects
- *
RETINAL vein occlusion , *DIABETIC retinopathy , *MACULAR edema , *DIABETES complications , *RETINAL diseases - Abstract
Retinal vein occlusion (RVO) is the most common vascular retinopathy after diabetic retinopathy. They include central retinal vein occlusions (CRVOs) and branch retinal vein occlusions (BRVOs). Macular edema (MO) marks a major turning point in the evolution of the disease, in fact, it is the main cause of reduced visual acuity. Scientific advances have been able to shed light on the main agent involved in the mechanisms of modulation of vascular permeability, namely, vascular endothelial growth factor (VEGF) which is found in significant quantities in the vitreous cavity and aqueous humor of patients with retinal microangiopathies, such as RVO. Thus, the development of substances capable of counteracting angiogenic factors seems clear in the treatment of microangiopathies. Today, in our context, Bevacizumab, although it does not have marketing authorization (MA) for this indication, is the most accessible anti-VEGF molecule. It is a recombinant humanized monoclonal antibody that selectively binds to VEGF, inhibiting its action. The study that we have assembled around this theme is a non-interventional analytical retrospective study compiled in our department involving 30 cases (32 eyes) and spanning a period of 24 months. The results of our study showed an improvement in visual acuity of around 25 letters according to the Early Treatment Diabetic Retinopathy Study (EDTRS) scale with a reduction in the average centro-foveolar thickness of the order of 180 μm, 12 months after the 1st intravitreal injection of Bevacizumab. This work aims to highlight the effectiveness of Bevacizumab on visual acuity and macular thickness in macular edema secondary to retinal vein occlusion and to remove part of the mystery surrounding this pathology, which at day today, has not yet revealed all its secrets. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF